Logo image of DCPH

DECIPHERA PHARMACEUTICALS IN (DCPH) Stock Fundamental Analysis

NASDAQ:DCPH - Nasdaq - US24344T1016 - Common Stock - Currency: USD

25.59  +0.02 (+0.08%)

After market: 25.61 +0.02 (+0.08%)

Fundamental Rating

4

Taking everything into account, DCPH scores 4 out of 10 in our fundamental rating. DCPH was compared to 556 industry peers in the Biotechnology industry. DCPH has a great financial health rating, but its profitability evaluates not so good. DCPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DCPH has reported negative net income.
DCPH had a negative operating cash flow in the past year.
In the past 5 years DCPH always reported negative net income.
In the past 5 years DCPH always reported negative operating cash flow.
DCPH Yearly Net Income VS EBIT VS OCF VS FCFDCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

DCPH's Return On Assets of -45.24% is in line compared to the rest of the industry. DCPH outperforms 52.53% of its industry peers.
DCPH has a Return On Equity of -60.25%. This is comparable to the rest of the industry: DCPH outperforms 58.99% of its industry peers.
Industry RankSector Rank
ROA -45.24%
ROE -60.25%
ROIC N/A
ROA(3y)-50.14%
ROA(5y)-44.56%
ROE(3y)-68.79%
ROE(5y)-58.11%
ROIC(3y)N/A
ROIC(5y)N/A
DCPH Yearly ROA, ROE, ROICDCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

DCPH's Gross Margin of 96.95% is amongst the best of the industry. DCPH outperforms 97.91% of its industry peers.
DCPH's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for DCPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5YN/A
DCPH Yearly Profit, Operating, Gross MarginsDCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

DCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DCPH has more shares outstanding
Compared to 5 years ago, DCPH has more shares outstanding
There is no outstanding debt for DCPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DCPH Yearly Shares OutstandingDCPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
DCPH Yearly Total Debt VS Total AssetsDCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

DCPH has an Altman-Z score of 7.32. This indicates that DCPH is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of DCPH (7.32) is better than 83.07% of its industry peers.
DCPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.32
ROIC/WACCN/A
WACC8.89%
DCPH Yearly LT Debt VS Equity VS FCFDCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.19 indicates that DCPH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.19, DCPH is in line with its industry, outperforming 45.03% of the companies in the same industry.
DCPH has a Quick Ratio of 3.94. This indicates that DCPH is financially healthy and has no problem in meeting its short term obligations.
DCPH has a Quick ratio (3.94) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 3.94
DCPH Yearly Current Assets VS Current LiabilitesDCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.96% over the past year.
Looking at the last year, DCPH shows a very strong growth in Revenue. The Revenue has grown by 26.51%.
The Revenue has been growing by 57.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)5.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)26.51%
Revenue growth 3Y57.16%
Revenue growth 5YN/A
Sales Q2Q%27.22%

3.2 Future

The Earnings Per Share is expected to grow by 18.21% on average over the next years. This is quite good.
Based on estimates for the next years, DCPH will show a very strong growth in Revenue. The Revenue will grow by 25.42% on average per year.
EPS Next Y5.08%
EPS Next 2Y14.35%
EPS Next 3Y20.37%
EPS Next 5Y18.21%
Revenue Next Year25.31%
Revenue Next 2Y26.97%
Revenue Next 3Y32.58%
Revenue Next 5Y25.42%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DCPH Yearly Revenue VS EstimatesDCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
DCPH Yearly EPS VS EstimatesDCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DCPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DCPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DCPH Price Earnings VS Forward Price EarningsDCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DCPH Per share dataDCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as DCPH's earnings are expected to grow with 20.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y20.37%

More info and screens

0

5. Dividend

5.1 Amount

DCPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DECIPHERA PHARMACEUTICALS IN

NASDAQ:DCPH (6/10/2024, 8:00:00 PM)

After market: 25.61 +0.02 (+0.08%)

25.59

+0.02 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10 2024-05-10/bmo
Earnings (Next)08-07 2024-08-07/bmo
Inst Owners6.97%
Inst Owner Change0%
Ins Owners26.79%
Ins Owner Change0%
Market Cap2.21B
Analysts71.25
Price Target27.25 (6.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.41%
Min EPS beat(2)8.03%
Max EPS beat(2)8.79%
EPS beat(4)4
Avg EPS beat(4)8.32%
Min EPS beat(4)6.6%
Max EPS beat(4)9.87%
EPS beat(8)7
Avg EPS beat(8)5.71%
EPS beat(12)8
Avg EPS beat(12)3.61%
EPS beat(16)12
Avg EPS beat(16)5.04%
Revenue beat(2)1
Avg Revenue beat(2)-3.37%
Min Revenue beat(2)-9.86%
Max Revenue beat(2)3.11%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-9.86%
Max Revenue beat(4)7.77%
Revenue beat(8)5
Avg Revenue beat(8)0.97%
Revenue beat(12)8
Avg Revenue beat(12)1.76%
Revenue beat(16)12
Avg Revenue beat(16)51.69%
PT rev (1m)1.26%
PT rev (3m)17.06%
EPS NQ rev (1m)9.43%
EPS NQ rev (3m)8.94%
EPS NY rev (1m)1.43%
EPS NY rev (3m)3.18%
Revenue NQ rev (1m)2.15%
Revenue NQ rev (3m)1.7%
Revenue NY rev (1m)0.68%
Revenue NY rev (3m)0.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.65
P/FCF N/A
P/OCF N/A
P/B 7
P/tB 7
EV/EBITDA N/A
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS2.02
BVpS3.65
TBVpS3.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.24%
ROE -60.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.95%
FCFM N/A
ROA(3y)-50.14%
ROA(5y)-44.56%
ROE(3y)-68.79%
ROE(5y)-58.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5YN/A
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.04%
Cap/Sales 0.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.19
Quick Ratio 3.94
Altman-Z 7.32
F-Score4
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)87.89%
Cap/Depr(5y)217.78%
Cap/Sales(3y)2.44%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y5.08%
EPS Next 2Y14.35%
EPS Next 3Y20.37%
EPS Next 5Y18.21%
Revenue 1Y (TTM)26.51%
Revenue growth 3Y57.16%
Revenue growth 5YN/A
Sales Q2Q%27.22%
Revenue Next Year25.31%
Revenue Next 2Y26.97%
Revenue Next 3Y32.58%
Revenue Next 5Y25.42%
EBIT growth 1Y-9.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.52%
EBIT Next 3Y4.87%
EBIT Next 5YN/A
FCF growth 1Y33.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.37%
OCF growth 3YN/A
OCF growth 5YN/A